Literature DB >> 1648248

Opioid delta agonists and endogenous enkephalins induce different emotional reactivity than mu agonists after injection in the rat ventral tegmental area.

G Calenco-Choukroun1, V Daugé, G Gacel, J Féger, B P Roques.   

Abstract

The possible role of opioid receptor heterogeneity in the biphasic changes in locomotion (activation and inhibition) induced by non-selective opiates such as morphine, has been investigated by measuring the behaviour of rats exposed to different environments after injection into the ventral tegmental area, of selective mu (DAGO) or delta (DTLET, DSTBULET, BUBU) opioid agonists and of kelatorphan, a complete inhibitor of enkephalin metabolism. delta agonists or kelatorphan-induced hyperactivity in a familiar (actimeter), unfamiliar (four-hole box) and a fear inducing (open-field) environment. These effects were suppressed by naloxone and delta selective antagonists (ICI 174, 864 2 mg/kg SC, naltrindole 7 nmol in the ventral tegmental area). Moreover, the delta agonists and endogenous enkephalins protected by kelatorphan did not affect the emotional state of rats measured in an elevated plus maze. Infused into the ventral tegmental area, DAGO also enhanced locomotion in the actimeter but in contrast to delta agonists and kelatorphan, the mu agonist decreased activity in the open-field and the four-hole box. The hypoactivity observed in these tests could be related to an enhanced emotionality produced by mu receptor stimulation, as shown by the significant decrease in the number of visits and time spent in open arms of the elevated plus maze. Naloxone (0.3 mg/kg SC) but not delta selective antagonists, blocked the various responses induced by DAGO.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1648248     DOI: 10.1007/bf02244249

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  47 in total

1.  Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists.

Authors:  P S Portoghese; M Sultana; H Nagase; A E Takemori
Journal:  J Med Chem       Date:  1988-02       Impact factor: 7.446

2.  Stimulant effects of enkephalin microinjection into the dopaminergic A10 area.

Authors:  C L Broekkamp; A G Phillips; A R Cools
Journal:  Nature       Date:  1979-04-05       Impact factor: 49.962

3.  ICI 174864: a highly selective antagonist for the opioid delta-receptor.

Authors:  R Cotton; M G Giles; L Miller; J S Shaw; D Timms
Journal:  Eur J Pharmacol       Date:  1984-01-27       Impact factor: 4.432

4.  Reward produced by microinjection of (D-Ala2),Met5-enkephalinamide into the ventral tegmental area.

Authors:  A G Phillips; F G LePiane
Journal:  Behav Brain Res       Date:  1982-06       Impact factor: 3.332

5.  The behavioural effects of enkephalin analogues injected into the ventral tegmental area and globus pallidus.

Authors:  E M Joyce; G F Koob; R Strecker; S D Iversen; F E Bloom
Journal:  Brain Res       Date:  1981-09-28       Impact factor: 3.252

6.  Autoradiographic comparison of the distribution of the neutral endopeptidase "enkephalinase" and of mu and delta opioid receptors in rat brain.

Authors:  G Waksman; E Hamel; M C Fournié-Zaluski; B P Roques
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

7.  Autoradiographic localization of mu-opioid and neurotensin receptors within the mesolimbic dopamine system.

Authors:  R P Dilts; P W Kalivas
Journal:  Brain Res       Date:  1989-05-29       Impact factor: 3.252

8.  Opiate rewarding action: independence of the cells of the lateral hypothalamus.

Authors:  M D Britt; R A Wise
Journal:  Brain Res       Date:  1981-10-05       Impact factor: 3.252

9.  The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice.

Authors:  B P Roques; M C Fournié-Zaluski; E Soroca; J M Lecomte; B Malfroy; C Llorens; J C Schwartz
Journal:  Nature       Date:  1980-11-20       Impact factor: 49.962

10.  Analogues of beta-LPH61-64 possessing selective agonist activity at mu-opiate receptors.

Authors:  B K Handa; A C Land; J A Lord; B A Morgan; M J Rance; C F Smith
Journal:  Eur J Pharmacol       Date:  1981-04-09       Impact factor: 4.432

View more
  13 in total

Review 1.  Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain.

Authors:  Bernard P Roques; Marie-Claude Fournié-Zaluski; Michel Wurm
Journal:  Nat Rev Drug Discov       Date:  2012-04       Impact factor: 84.694

2.  New CCK2 agonists confirming the heterogeneity of CCK2 receptors: characterisation of BBL454.

Authors:  Bruno Bellier; Dominique Crété; Marie-Emmanuelle Million; Françoise Beslot; André Bado; Christiane Garbay; Valérie Daugé
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-10-08       Impact factor: 3.000

3.  Next generation effects of female adolescent morphine exposure: sex-specific alterations in response to acute morphine emerge before puberty.

Authors:  Fair M Vassoler; Nicole L Johnson-Collins; Lindsay M Carini; Elizabeth M Byrnes
Journal:  Behav Pharmacol       Date:  2014-04       Impact factor: 2.293

4.  Wireless Optofluidic Systems for Programmable In Vivo Pharmacology and Optogenetics.

Authors:  Jae-Woong Jeong; Jordan G McCall; Gunchul Shin; Yihui Zhang; Ream Al-Hasani; Minku Kim; Shuo Li; Joo Yong Sim; Kyung-In Jang; Yan Shi; Daniel Y Hong; Yuhao Liu; Gavin P Schmitz; Li Xia; Zhubin He; Paul Gamble; Wilson Z Ray; Yonggang Huang; Michael R Bruchas; John A Rogers
Journal:  Cell       Date:  2015-07-16       Impact factor: 41.582

5.  Deletion of CCK2 receptor in mice results in an upregulation of the endogenous opioid system.

Authors:  Blandine Pommier; Françoise Beslot; Axelle Simon; Matthieu Pophillat; Toshimitsu Matsui; Valérie Dauge; Bernard P Roques; Florence Noble
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

6.  Rats rapidly develop tolerance to the locomotor-inhibiting effects of the novel neuropeptide orphanin FQ.

Authors:  D P Devine; L Taylor; R K Reinscheid; F J Monsma; O Civelli; H Akil
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

7.  Two delta opioid receptor subtypes are functional in single ventral tegmental area neurons, and can interact with the mu opioid receptor.

Authors:  Elyssa B Margolis; Wakako Fujita; Lakshmi A Devi; Howard L Fields
Journal:  Neuropharmacology       Date:  2017-06-21       Impact factor: 5.250

8.  Use of preproenkephalin knockout mice and selective inhibitors of enkephalinases to investigate the role of enkephalins in various behaviours.

Authors:  Florence Noble; Nadia Benturquia; Andras Bilkei-Gorzo; Andreas Zimmer; Bernard P Roques
Journal:  Psychopharmacology (Berl)       Date:  2007-10-01       Impact factor: 4.530

9.  Long-term sensitization to the activation of cerebral delta-opioid receptors by the deltorphin Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 in rats exposed to morphine.

Authors:  P Melchiorri; M Maritati; L Negri; V Erspamer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

10.  Central HIV-1 Tat exposure elevates anxiety and fear conditioned responses of male mice concurrent with altered mu-opioid receptor-mediated G-protein activation and β-arrestin 2 activity in the forebrain.

Authors:  Yun K Hahn; Jason J Paris; Aron H Lichtman; Kurt F Hauser; Laura J Sim-Selley; Dana E Selley; Pamela E Knapp
Journal:  Neurobiol Dis       Date:  2016-02-01       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.